TRAVATAN Z Drug Patent Profile

Which patents cover Travatan Z, and what generic alternatives are available?

Travatan Z is a drug marketed by Sandoz and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-five patent family members in twenty-three countries.

The generic ingredient in TRAVATAN Z is travoprost. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Travatan Z

A generic version of TRAVATAN Z was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for TRAVATAN Z

International Patents:	45
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	53
Patent Applications:	4,008
Drug Prices:	Drug price information for TRAVATAN Z
Drug Sales Revenues:	Drug sales revenues for TRAVATAN Z
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRAVATAN Z
What excipients (inactive ingredients) are in TRAVATAN Z?	TRAVATAN Z excipients list
DailyMed Link:	TRAVATAN Z at DailyMed

See drug prices for TRAVATAN Z

See drug sales revenues for TRAVATAN Z

Recent Clinical Trials for TRAVATAN Z

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Hong Kong	N/A
Laboratorios Sophia S.A de C.V.	Phase 1
Novartis Pharmaceuticals	Phase 4

See all TRAVATAN Z clinical trials

Pharmacology for TRAVATAN Z

Drug Class

Prostaglandin Analog

Paragraph IV (Patent) Challenges for TRAVATAN Z

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRAVATAN Z	Ophthalmic Solution	travoprost	0.004%	021994	1	2009-02-19

US Patents and Regulatory Information for TRAVATAN Z

TRAVATAN Z is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT	RX	Yes	Yes			Y

Expired US Patents for TRAVATAN Z

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006

EU/EMA Drug Approvals for TRAVATAN Z

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

International Patents for TRAVATAN Z

See the table below for patents covering TRAVATAN Z around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	062929	COMPOSICIONES FARMACEUTICAS ACUOSAS AUTOCONSERVADAS
European Patent Office	2068822	COMPOSITIONS PHARMACEUTIQUES AQUEUSES AUTO-CONSERVÉES (SELF PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS)
Japan	H07506377
Denmark	0639070
Hong Kong	1126667	SELF PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS

Supplementary Protection Certificates for TRAVATAN Z

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1920764	CA 2012 00030	Denmark
1920764	C300540	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
1920764	92058	Luxembourg		92058, EXPIRES: 20161127
1514548	C300671	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128
1920764	C01920764/01	Switzerland		PRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002

TRAVATAN Z Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Travatan Z

Introduction

Travatan Z, a brand-name prescription drug containing the active ingredient travoprost, is used to treat increased eye pressure caused by ocular hypertension or open-angle glaucoma. Here, we delve into the market dynamics and financial trajectory of this medication.

Market Position and Competition

Travatan Z is part of the prostaglandin analogs class of medications, which are widely used in the treatment of glaucoma and ocular hypertension. The market for these medications is competitive, with other notable drugs like latanoprost (Xalatan) also available.

• Generic Alternatives: Recently, Glenmark Pharmaceuticals launched a generic formulation of travoprost, which is bioequivalent and therapeutically equivalent to Travatan Z. This introduction of a generic alternative is likely to impact the market share and pricing of Travatan Z[4].

Sales and Revenue

Travatan Z has maintained a significant presence in the market, despite the competition.

• Annual Sales: According to IQVIA sales data, Travatan Z achieved annual sales of approximately $66.2 million for the 12-month period ending September 2024. This figure indicates a stable revenue stream for the drug[4].

Pricing and Cost Considerations

The cost of Travatan Z is a critical factor in its market dynamics.

• Brand-Name vs. Generic: As a brand-name drug, Travatan Z is generally more expensive than its generic counterparts. The introduction of generic travoprost by Glenmark is expected to offer a more affordable option for patients, potentially affecting the sales of Travatan Z[1][4].

• Insurance and Mail-Order Pharmacies: The cost of Travatan Z can be mitigated through insurance coverage and mail-order pharmacy services. Some Medicare plans may help cover the cost, and mail-order pharmacies can provide a 90-day supply, reducing the financial burden on patients[1].

Effectiveness and Clinical Outcomes

The effectiveness of Travatan Z in reducing eye pressure is a key factor in its market success.

• Clinical Trials: Studies have shown that Travatan Z can reduce intraocular pressure (IOP) by 7 to 8 mmHg in patients with baseline pressures of 25 to 27 mmHg. This efficacy is comparable to other prostaglandin analogs like latanoprost[3].

Side Effects and Patient Compliance

The side effect profile of Travatan Z influences patient compliance and market acceptance.

• Common Side Effects: The most common side effect is eye redness (conjunctival hyperemia), reported in 30% to 50% of patients. Other side effects include changes in iris pigmentation, which can be permanent, and reversible changes in eyelashes and eyelids[1][3].

Manufacturer and Distribution

Novartis, the manufacturer of Travatan Z, plays a significant role in its market dynamics.

• Financial Performance: Novartis has reported strong financial performance in recent years, with core operating income and net sales increasing. However, the integration costs and other exceptional charges related to acquisitions like Alcon have impacted their overall financials[2][5].

Market Trends and Future Outlook

The ophthalmic drug market is evolving, with several trends affecting Travatan Z.

• Generic Competition: The launch of generic travoprost by Glenmark is expected to increase competition and potentially reduce the market share of Travatan Z. This trend may lead to price adjustments and marketing strategies to retain market position[4].

• Patient Preferences: Patients are increasingly seeking affordable and effective treatments. The availability of generic options may shift patient preferences, influencing the financial trajectory of Travatan Z.

Financial Trajectory

The financial trajectory of Travatan Z is influenced by several factors:

• Revenue Stability: Despite competition, Travatan Z has maintained significant annual sales, indicating a stable revenue stream[4].

• Cost and Pricing: The introduction of generic alternatives is likely to impact pricing strategies. Travatan Z may need to adjust its pricing to remain competitive[1][4].

• Manufacturer's Financial Health: Novartis's overall financial health, including its core operating income and net sales, will continue to influence the investment and marketing efforts for Travatan Z[2][5].

Key Takeaways

• Market Competition: Travatan Z faces competition from generic alternatives and other prostaglandin analogs.
• Pricing and Cost: The drug is more expensive than generic options, but mail-order pharmacies and insurance can mitigate costs.
• Effectiveness: Travatan Z is effective in reducing IOP, with clinical outcomes comparable to other treatments.
• Side Effects: Common side effects include eye redness and changes in iris pigmentation.
• Financial Performance: The drug maintains significant annual sales, but faces pricing pressure from generics.

FAQs

Q: What is Travatan Z used for? A: Travatan Z is used to treat increased eye pressure caused by ocular hypertension or open-angle glaucoma.

Q: What are the common side effects of Travatan Z? A: The most common side effect is eye redness (conjunctival hyperemia), followed by changes in iris pigmentation and reversible changes in eyelashes and eyelids.

Q: Is there a generic version of Travatan Z available? A: Yes, Glenmark Pharmaceuticals has launched a generic formulation of travoprost, which is bioequivalent and therapeutically equivalent to Travatan Z.

Q: How does Travatan Z compare to other prostaglandin analogs in terms of effectiveness? A: Travatan Z is as effective as other prostaglandin analogs like latanoprost in reducing intraocular pressure.

Q: Can Travatan Z be obtained through mail-order pharmacies? A: Yes, Travatan Z may be available through mail-order pharmacies, which can help lower the drug’s cost and ensure a steady supply.

Sources

1. Medical News Today: Travatan Z: Generic form, side effects, cost, alternatives, and more.
2. GlobeNewswire: Novartis delivers strong underlying financial performance in 2011.
3. Novartis: TRAVATAN Z®.
4. Financial Express: Glenmark launches generic formulation for Glaucoma in United States.
5. FierceBiotech: Novartis achieves strong third quarter financial performance and pipeline progress.